Clincosm LogoSign in Get a demo

chemoradiotherapy

Showing 1 - 25 of 28
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical

Recruiting
  • Cervical Cancer
  • +2 more
  • Treatment Group
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
May 9, 2023

Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Immunonutrition Trial in Hefei (Whole-course Immunonutrition Combined

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • +3 more
  • Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
  • Hefei, China
    Anhui provincial hospital
Apr 16, 2023

Uterine Cervical Tumors, Chemoradiotherapy, Adjuvant Chemo Trial in Liuzhou (paclitaxel combined with platinum)

Recruiting
  • Uterine Cervical Neoplasms
  • +2 more
  • paclitaxel combined with platinum
  • Liuzhou, Guangxi, China
    the Fourth Affiliated Hospital of Guangxi Medical University
Feb 16, 2023

Locally Advanced NSCLC, Chemoradiotherapy, Cavitation Lung Trial (Upfront resection)

Not yet recruiting
  • Locally Advanced Non-Small Cell Lung Cancer
  • +5 more
  • Upfront resection
  • (no location specified)
Nov 9, 2022

Head and Neck Tumor, Chemoradiotherapy Trial in Taichung (SZKJT(San-Zhong-Kui-Jian-Tang))

Completed
  • Head and Neck Neoplasm
  • Chemoradiotherapy
  • Taichung, Taiwan
    China Medical University Hospital
Oct 24, 2022

Uterine Cervical Tumors, Chemoradiotherapy, Angiogenesis Trial in Wuhan (Hydrochloride anlotinib, cis Platinum/carboplatin,

Recruiting
  • Uterine Cervical Neoplasms
  • +2 more
  • Hydrochloride anlotinib
  • +2 more
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
May 17, 2022

Head and Neck Tumors, Chemoradiotherapy, Stomatitis and Ulceration Trial in Keelung (Herbal gargle, Normal saline)

Not yet recruiting
  • Head and Neck Neoplasms
  • +2 more
  • Herbal gargle
  • Normal saline
  • Keelung, Keelung, Taiwan, Taiwan
    Keelung Chang Gung Memorial Hospital
Apr 18, 2022

Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1 Trial in Beijing (Camrelizumab plus Concurrent

Recruiting
  • Cervical Carcinoma
  • +8 more
  • Camrelizumab plus Concurrent chemoradiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 5, 2022

Rectal Cancer, Chemoradiotherapy, Watch & Wait Trial in Seoul (Capecitabine)

Recruiting
  • Rectal Cancer
  • +2 more
  • Seoul, Korea, Republic of
    Kangbuk Samsung Hospital
Mar 30, 2022

Rectal Cancer, Adenocarcinoma, Chemoradiotherapy Trial in Sabadell (prehabilitation)

Not yet recruiting
  • Rectal Cancer, Adenocarcinoma
  • Chemoradiotherapy
  • prehabilitation
  • Sabadell, Barcelona, Spain
    Laura Mora López
Mar 17, 2022

Stomach Tumors, Esophagogastric Junction Disorder, Neoadjuvant Therapy Trial in Shanghai (drug, radiation, procedure)

Recruiting
  • Stomach Neoplasms
  • +7 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Dec 3, 2021

Colorectal Tumors Malignant, Lymph Node Excision, Chemoradiotherapy Trial in Jinan (Radical surgery with PALND, Radical surgery

Not yet recruiting
  • Colorectal Neoplasms Malignant
  • +2 more
  • Radical surgery with PALND
  • Radical surgery without PALND
  • Jinan, Shandong, China
    Qilu Hospital of Shandong University
Nov 18, 2021

Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Survival Trial in Nanjing, Shanghai (Paclitaxel plus carboplatin,

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Paclitaxel plus carboplatin
  • radiotherapy
  • Nanjing, Jiangsu, China
  • +2 more
Oct 31, 2021

Esophageal Cancer, Chemoradiotherapy, Nimotuzumab Trial in Beijing (Radiotherapy, Nimotuzumab, S-1)

Recruiting
  • Esophageal Cancer
  • +3 more
  • Radiotherapy
  • +2 more
  • Beijing, China
    Department of Radiation Oncology, National Cancer Center/Nationa
Oct 21, 2021

Immunological, Molecular-genetic, Image-based and Microbial

Recruiting
  • Oncology
  • +4 more
  • Non-interventional
  • Munich, Bavaria, Germany
    LMU University Hospital
Aug 31, 2021

Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel Trial in Beijing (Radiotherapy, Albumin-Bound Paclitaxel,

Recruiting
  • Esophageal Cancer
  • +3 more
  • Radiotherapy
  • +2 more
  • Beijing, China
    Department of Radiation Oncology, National Cancer Center/Nationa
Aug 16, 2021

Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease Trial in Beijing (PD-1 antibody, Chemoradiation, Albumin-Bound

Recruiting
  • Esophagus Cancer
  • +3 more
  • PD-1 antibody
  • +3 more
  • Beijing, Beijing, China
    Department of Radiation Oncology, National Cancer Center/Nationa
Mar 26, 2021

Esophagus Cancer, Esophageal Squamous Cell Carcinoma, Chemoradiotherapy Trial in Shanghai (Paclitaxel, Carboplatin,

Recruiting
  • Esophagus Cancer
  • +4 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 19, 2021

Immunoconsolidation Therapy for Locally Advanced NSCLC After

Recruiting
  • NSCLC
  • +2 more
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Feb 3, 2021

    Esophageal Squamous Cell Carcinoma, Enteral Nutrition Therapy, Chemoradiotherapy Trial in Chengdu (Enteral nutrition,

    Completed
    • Esophageal Squamous Cell Carcinoma
    • +2 more
    • Enteral nutrition
    • radiotherapy
    • Chengdu, Sichuan, China
      Sichuan Cancer Hospital & Institute
    Mar 16, 2020

    Neoadjuvant Chemoradiotherapy for Rectal Cancer

    Unknown status
    • Rectal Neoplasm Malignant Carcinoma
    • +4 more
    • Radiation
    • Capecitabine-Irinotecan Combination
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Jan 11, 2020

    Different Nutritional Pathways on Improving Nutritional Status

    Unknown status
    • Esophageal Squamous Cell Carcinoma
    • +2 more
    • Dietary guidance
    • Tianjin, Tianjin, China
      Department of Radiation Oncology, Tianjin Medical University can
    Dec 12, 2019

    Stomach Tumors, Neoadjuvant Therapy, Chemoradiotherapy Trial in Beijing (radiation, drug, procedure)

    Completed
    • Stomach Neoplasms
    • +3 more
    • SIB-IMRT
    • +3 more
    • Beijing, China
      Department of Radiation Oncology, Cancer Hospital, Chinese Acade
    Oct 15, 2019

    PD-1, Chemoradiotherapy, Gastroesophageal Junction Cancer Trial (PD-1)

    Not yet recruiting
    • PD-1
    • +2 more
    • (no location specified)
    Aug 17, 2019

    Upfront Bevacizumab/témozolomide for Gliomastomas With

    Completed
    • Chemoradiotherapy
    • TMZ and BEV induction before chemoradiotherapy
    • (no location specified)
    Aug 6, 2018